Journal article

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

Robson Zazula, Muhammad Ishrat Husain, Mohammadreza Mohebbi, Adam J Walker, Imran B Chaudhry, Ameer B Khoso, Melanie M Ashton, Bruno Agustini, Nusrat Husain, JFW Deakin, Allan H Young, Michael Berk, Buranee Kanchanatawan, Chee H Ng, Michael Maes, Lesley Berk, Ajeet B Singh, Gin S Malhi, Olivia M Dean



BACKGROUND: Randomized controlled clinical trials that have investigated minocycline as an adjunctive treatment for major depressive disorder have proved promising. Data from two studies were pooled to evaluate more definitively whether the addition of minocycline to standard treatment for major depressive disorder leads to an improvement of depressive symptoms when compared with placebo. METHODS: Both studies were multi-site, double-blinded, placebo-controlled trials of minocycline 200 mg/day added to treatment as usual during a 12-week period. The primary outcome measure was change in depressive symptoms (Montgomery-Asberg Depression Rating Scale in Dean et al. and Hamilton Depression Rati..

View full abstract


Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The Dean et al. (2017) clinical trial was funded by the Brain and Behavior Foundation and Australasian Society for Bipolar and Depressive Disorders/Servier grant and the authors gratefully acknowledge their support. The Husain et al. (2017a) trial was part funded by the Pakistan Institute of Living and Learning and the National Institute of Health Research Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King's College London. The authors would like to acknowledge the service support of Barwon Health, Deakin University, The Melbourne Clinic, The University of Melbourne and Chulalongkorn University.